U.S. FDA Clears Pluristem ’s IND Application for Phase II COVID-19 Study

HAIFA, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that the...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials